Voncento®

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Von Willebrand Disease

Conditions

Von Willebrand Disease

Trial Timeline

Nov 23, 2015 → Dec 31, 2023

NCT ID

NCT04657887

About Voncento®

Voncento® is a pre-clinical stage product being developed by CSL for Von Willebrand Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04657887. Target conditions include Von Willebrand Disease.

What happened to similar drugs?

4 of 7 similar drugs in Von Willebrand Disease were approved

Approved (4) Terminated (0) Active (3)

✅Blood coagulation Factor VIII and vWF, humanCSLApproved

✅VoncentoCSLApproved

✅Alphanate SD/HTGrifolsApproved

✅plasma-derived FVIII/VWF concentrateGrifolsApproved

🔄Emicizumab + von Willebrand Factor (VWF) Concentrates + Factor VIII (FVIII) Concentrates + von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates + Bypassing AgentsRochePhase 3

🔄BiostateCSLPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04657887	Pre-clinical	Completed	Nov 23, 2015	Dec 31, 2023	Von Willebrand Disease

Competing Products

14 competing products in Von Willebrand Disease

See all competitors

Product	Company	Stage	Hype Score
Von Willebrand Factor Concentrates + Von Willebrand Factor Concentrates and Factor VIII Concentrates + Factor VIII Concentrates + Recombinant Activated Factor VII + Activated Prothrombin Complex Concentrate	Roche	Pre-clinical	33
Emicizumab + von Willebrand Factor (VWF) Concentrates + Factor VIII (FVIII) Concentrates + von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates + Bypassing Agents	Roche	Phase 3	47
Neumega (Oprelvekin, Interleukin 11, IL-11)	Pfizer	Phase 2	27
Oprelvekin, Interleukin 11, IL-11	Pfizer	Phase 2	35
recombinant interleukin-11 + recombinant interleukin-11 + recombinant interleukin-11	Pfizer	Phase 2	35
efanesoctocog alfa (BIVV001)	Sanofi	Phase 1	29
Biostate	CSL	Phase 3	40
Blood coagulation Factor VIII and vWF, human	CSL	Approved	43
Biostate® + Biostate®	CSL	Phase 2/3	38
VWF/FVIII products	CSL	Pre-clinical	26
Biostate	CSL	Phase 3	40
Voncento	CSL	Approved	43
Alphanate SD/HT	Grifols	Approved	44
plasma-derived FVIII/VWF concentrate	Grifols	Approved	47